Skip to content

Investigating the Efficacy and Safety of Oroxylum Indicum Extract on Overweight and Obese Subjects: A Randomized Controlled Clinical Trial (A Pilot Study)

Investigating the Efficacy and Safety of Oroxylum Indicum Extract on Overweight and Obese Subjects: A Randomized Controlled Clinical Trial (A Pilot Study)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200520001
Enrollment
Unknown
Registered
2020-05-20
Start date
2020-07-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight&#44

Interventions

Placebo starch capsule,20 mg of simvastatin positive control drug,1.6 g of garlic extract ,1.6 g of O. indicum extract (high dose),0.5 g of O. indicum extract (low dose)
Placebo Comparator No treatment,Active Comparator Drug,Active Comparator Dietary Supplement,Experimental Dietary Supplement,Experimental Dietary Supplement
Placebo,SIM,GE,OIE(H),OIE(L)

Sponsors

Suranaree University of Technology
Lead Sponsor
Suranaree University of Technology
Collaborator

Eligibility

Sex/Gender
All
Age
30 Years to 60 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria: men and women 30 to 60 years of age, affected by overweight or obesity, with the body mass index (BMI) of 25–35 kg/m2 and without a previous diagnosis of cardiovascular disease

Exclusion criteria

Exclusion criteria: (1) coronary heart diseases, e.g. heart failure, myocardial infarction, arrhythmia; (2) endocrine disease, e.g. sex gland disorder, thyroid disorder, and pituitary disorder; (3) pregnant or lactating women; (4) taking medications or supplements and herbals that might interfere with blood glucose and lipid measurements. Subjects were excluded if they had side effects from the extract.

Design outcomes

Primary

MeasureTime frame
anti-hyperlipidemia effect 12 week (measure every month) Serum lipid (Cholesterol, Triglyceride, LDL-C and HDL-C) measurement

Secondary

MeasureTime frame
anti-hyperglycemia effect 12 week (measure every month) oral glucose tolerance testing

Countries

Thailand

Contacts

Public ContactGriangsak Eumkeb

Suranaree University of Teachnology

Griang@sut.ac.th0898650443

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026